Cargando…

Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy

Portal vein tumor thrombus (PVTT) is a frequent complication in hepatocellular carcinoma (HCC). HCC patients with PVTT have the characteristics of less treatment tolerance and poor prognosis. Immunotherapy, especially combined immunotherapy, has been successfully used in advanced HCC. However, there...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Kaihang, Xu, Yuyan, Cheng, Yuan, Wen, Yaohong, Cai, Lei, He, Guolin, Huang, Huakun, Fu, Shunjun, Zhong, Xuefeng, Zheng, Yating, Chen, Tingting, Huang, Mengli, Pan, Mingxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471014/
https://www.ncbi.nlm.nih.gov/pubmed/36119069
http://dx.doi.org/10.3389/fimmu.2022.999763
_version_ 1784788970846027776
author Zhong, Kaihang
Xu, Yuyan
Cheng, Yuan
Wen, Yaohong
Cai, Lei
He, Guolin
Huang, Huakun
Fu, Shunjun
Zhong, Xuefeng
Zheng, Yating
Chen, Tingting
Huang, Mengli
Pan, Mingxin
author_facet Zhong, Kaihang
Xu, Yuyan
Cheng, Yuan
Wen, Yaohong
Cai, Lei
He, Guolin
Huang, Huakun
Fu, Shunjun
Zhong, Xuefeng
Zheng, Yating
Chen, Tingting
Huang, Mengli
Pan, Mingxin
author_sort Zhong, Kaihang
collection PubMed
description Portal vein tumor thrombus (PVTT) is a frequent complication in hepatocellular carcinoma (HCC). HCC patients with PVTT have the characteristics of less treatment tolerance and poor prognosis. Immunotherapy, especially combined immunotherapy, has been successfully used in advanced HCC. However, there are no recognized universally indicators that can predict response or resistance to immunotherapy for HCC. Herein, we reported a 58-year-old HCC patient with PVTT, cirrhosis and chronic viral hepatitis, who achieved complete response (CR) after combined immunotherapy (camrelizumab combined with sorafenib or regorafenib), according to his high enrichment of tumor-infiltrating immune cells and tertiary lymphoid structure (TLS). In this case, we revealed the characteristics of the baseline tumor immune microenvironment (TIME) in a HCC patient who responded well to combined immunotherapy, suggesting that TIME can be used to assist in clinical decision making of immunotherapy for HCC.
format Online
Article
Text
id pubmed-9471014
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94710142022-09-15 Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy Zhong, Kaihang Xu, Yuyan Cheng, Yuan Wen, Yaohong Cai, Lei He, Guolin Huang, Huakun Fu, Shunjun Zhong, Xuefeng Zheng, Yating Chen, Tingting Huang, Mengli Pan, Mingxin Front Immunol Immunology Portal vein tumor thrombus (PVTT) is a frequent complication in hepatocellular carcinoma (HCC). HCC patients with PVTT have the characteristics of less treatment tolerance and poor prognosis. Immunotherapy, especially combined immunotherapy, has been successfully used in advanced HCC. However, there are no recognized universally indicators that can predict response or resistance to immunotherapy for HCC. Herein, we reported a 58-year-old HCC patient with PVTT, cirrhosis and chronic viral hepatitis, who achieved complete response (CR) after combined immunotherapy (camrelizumab combined with sorafenib or regorafenib), according to his high enrichment of tumor-infiltrating immune cells and tertiary lymphoid structure (TLS). In this case, we revealed the characteristics of the baseline tumor immune microenvironment (TIME) in a HCC patient who responded well to combined immunotherapy, suggesting that TIME can be used to assist in clinical decision making of immunotherapy for HCC. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471014/ /pubmed/36119069 http://dx.doi.org/10.3389/fimmu.2022.999763 Text en Copyright © 2022 Zhong, Xu, Cheng, Wen, Cai, He, Huang, Fu, Zhong, Zheng, Chen, Huang and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhong, Kaihang
Xu, Yuyan
Cheng, Yuan
Wen, Yaohong
Cai, Lei
He, Guolin
Huang, Huakun
Fu, Shunjun
Zhong, Xuefeng
Zheng, Yating
Chen, Tingting
Huang, Mengli
Pan, Mingxin
Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
title Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
title_full Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
title_fullStr Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
title_full_unstemmed Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
title_short Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
title_sort case report: primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471014/
https://www.ncbi.nlm.nih.gov/pubmed/36119069
http://dx.doi.org/10.3389/fimmu.2022.999763
work_keys_str_mv AT zhongkaihang casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT xuyuyan casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT chengyuan casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT wenyaohong casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT cailei casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT heguolin casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT huanghuakun casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT fushunjun casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT zhongxuefeng casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT zhengyating casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT chentingting casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT huangmengli casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy
AT panmingxin casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy